Melior Pharmaceuticals

10 articles about Melior Pharmaceuticals

• Melior Pharmaceuticals Announces Execution of License Agreement for Armesocarb by Adhera Therapeutics

  7/29/2021

  Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

• Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic

  3/9/2021

  Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies

• 

  2021 Biopharma Update on the Novel Coronavirus: March 9

  3/9/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.

• Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial

  9/15/2020

  Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies  

• Melior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes

  5/14/2019

  Melior Pharmaceuticals I, Inc announced that its novel first-in-class insulin sensitizer, tolimidone, has demonstrated significant reduction of HbA1c compared to placebo in a recently completed Phase 2B study involving patients with Type 2 diabetes mellitus in an analysis of all subjects who completed the full course of treatment.

• Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes

  10/16/2018

  Melior Pharmaceuticals is pleased to announce that it has randomized the last patient into its Phase 2b study for subjects with uncontrolled Type 2 diabetes on metformin therapy.

• Melior Pharmaceuticals Initiates Phase IIb Study With MLR-1023 For Type 2 Diabetes

  10/3/2017

• Melior Pharmaceuticals Announces Positive Phase IIA Results In Type 2 Diabetes Study

  6/13/2016

• Melior Discovery Announces Spinout of Melior Pharmaceuticals

  5/10/2016

• Melior Pharmaceuticals Achieves Partnership Milestone With Bukwang Pharm. Ind. Co., Ltd.

  3/15/2016